Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

Approvals Action
First copy of Halaven ticked

Posted 2 August 2021

Sandoz has become the first sponsor to register a generic version of Eisai's PBS-listed cancer drug Halaven.

Like Halaven, the company's injection dubbed Eribulin Sandoz is indicated as a second line treatment of patients with locally advanced or metastatic breast cancer and for patients with unresectable liposarcoma.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Timely support for meds regulator
Threats and harassment may warrant extra TGA powers
Approvals Action
Four new therapies ticked
Plus, the disputed first generic of MSD?s diabetes drug